NeRRe Therapeutics

NeRRe Therapeutics was a clinical-stage biotech founded in 2012, originating from a GSK spin-out, with a specialized focus on neurokinin receptor antagonists. Its lead asset, orvepitant, reached Phase II development for chronic refractory cough and other conditions. The company ultimately ceased operations, indicating a failure to secure further funding or a strategic exit, with its intellectual property and assets presumably managed by appointed administrators.

Small molecule antagonists targeting neurokinin receptors (NK1, NK2) for neuronal hypersensitivity disorders.

NeRRe competed in the novel chronic cough space against companies like Merck (gefapixant), Bellus Health (now GSK) (camlipixant), and Shionogi (eliapixant), all targeting the P2X3 receptor. This made the NK1 mechanism a differentiated but less clinically advanced approach, requiring robust data to compete for market share and partnership interest.